US2009004716A1PendingUtilityA1

Compositions comprising high concentration of biologically active molecules and processes for preparing the same

60
Assignee: VGX PHARMACEUTICLAS INCPriority: May 23, 2007Filed: May 23, 2008Published: Jan 1, 2009
Est. expiryMay 23, 2027(~0.9 yrs left)· nominal 20-yr term from priority
C12N 1/06C12N 15/1017C12N 15/10C07K 1/20C12M 1/12C12N 7/00C12Q 1/6806A61K 38/00
60
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

Large scale processes for producing high purity samples of biologically active molecules of interest from bacterial cells are disclosed. The methods comprise the steps of producing a lysate solution by contacting a cell suspension of said plurality of cells with lysis solution; neutralizing said lysate solution with a neutralizing solution to produce a dispersion that comprises neutralized lysate solution and debris; filtering the dispersion through at least one filter; performing ion exchange separation on said neutralized lysate solution to produce an ion exchange eluate; and performing hydrophobic interaction separation on said ion exchange eluate to produce a hydrophobic interaction solution. Further, provided are compositions comprising large scale amounts of plasmid DNA produced by the disclosed large scale processes.

Claims

exact text as granted — not AI-modified
1 . A large scale process for producing high purity samples of at least one biologically active molecule of interest from bacterial cells, comprising the steps of:
 a) producing a lysate solution by contacting a cell suspension of said plurality of cells with lysis solution;   b) neutralizing said lysate solution with a neutralizing solution to produce a dispersion that comprises neutralized lysate solution and debris;   c) filtering the dispersion through at least one filter;   d) performing ion exchange separation on said neutralized lysate solution to produce an ion exchange eluate; and   e) performing hydrophobic interaction separation on said ion exchange eluate to produce a hydrophobic interaction solution.   
     
     
         2 . The method of  claim 1 , wherein step a) comprises mixing said cell suspension with lysis solution in a high shear, in-line mixer. 
     
     
         3 . The method of  claim 1 , wherein step b) comprises mixing said lysate solution with said neutralizing solution in a bubble mixer. 
     
     
         4 . The method of claim any one of  claims 1 , wherein step e) comprises performing hydrophobic interaction separation using a hydrophobic interaction column or a hydrophobic interaction membrane to form a hydrophobic interaction solution. 
     
     
         5 . The method of any of  claims 1 , further comprising the step:
 f) preparing a solution of at least one biologically active molecule by ultrafiltration of said hydrophobic interaction solution.   
     
     
         6 . The method of  claims 5 , further comprising the step:
 g) preparing a sterile solution of at least one biologically active molecule by sterile filtration of said solution of biologically active molecules.   
     
     
         7 . The method of  claim 1 , further comprising holding the dispersion for a period of time to separate the neutralized lysate solution from the debris and filtering the neutralized lysate solution through at least one filter. 
     
     
         8 . The method of  claim 1 , wherein the producing step comprises contacting the cell suspension with the lysis solution in a mixer over a duration of from about 1 minutes to about 20 minutes. 
     
     
         9 . The method of  claim 8 , wherein the duration is from about 4 minutes to about 8 minutes. 
     
     
         10 . The method of  claim 8 , wherein the duration is about 5 minutes. 
     
     
         11 . The method of  claim 1 , wherein said biologically active molecule is a plasmid. 
     
     
         12 . The method of  claim 1  wherein said ion exchange is an anion exchange membrane. 
     
     
         13 . The method of  claim 1 , wherein step e) comprises performing hydrophobic interaction separation comprises butyl hydrophobic interaction chromatography in order to produce a hydrophobic interaction solution that is a butyl hydrophobic interaction chromatography solution eluate. 
     
     
         14 . The method of  claim 1 , wherein the method comprises transitioning from one step to a subsequent step substantially continuously and comprises separating the neutralized lysate solution from the debris in the dispersion by collecting the lysate in a container and passing the dispersion through a primary filter to produce an initial crude neutralized lysate solution. 
     
     
         15 . The method of  claim 14 , further comprising passing the first crude neutralized lysate solution through a secondary filter to produce a subsequent crude neutralized lysate solution. 
     
     
         16 . A large scale process for producing high purity samples of at least one biologically active molecule of interest from bacterial cells, comprising the steps of:
 contacting the bacterial cells in a dispersion of cells with lysis solution to form a lysate solution;   neutralizing the lysate solution by mixing a neutralization solution into the lysate solution with a bubble column mixer to form a neutralized mixture;   filtering the neutralized mixture through a primary filter and a secondary filter to form a filtered solution;   passing the filtered solution through an ion-exchange column to form a ion-exchange solution;   passing the ion-exchange solution through a hydrophobic interaction column or a hydrophobic interaction membrane to form a hydrophobic interaction solution; and   ultrafiltration of the hydrophobic interaction solution to form a high purity sample of at least one biologically active molecules of interest;   wherein each transition from one step to a subsequent step in the large scale process from the contacting step to the passing the filtered solution step occur substantially continuously.   
     
     
         17 . A composition comprising of at least one biologically active molecule of interest prepared by the method of  claims 1 , wherein at least one biologically active molecule of interest is a DNA plasmid. 
     
     
         18 . The composition of  claim 17 , where the composition comprises DNA plasmids at a quantity of about 10 mg or more in solution, wherein the high purity of said plasmids is the plasmids being present at greater than about 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99%. 
     
     
         19 . The composition of  claim 18 , wherein the purity of said plasmid is greater than about 99%. 
     
     
         20 . The composition of  claim 18 , wherein concentration of plasmid in the solution is about 5, 6, 7, 8, 9, 10, 11, 12, or 13 mg/mL. 
     
     
         21 . The composition of  claim 18 , wherein said plasmid comprises greater than about 50% supercoiled plasmid. 
     
     
         22 . The composition of  claim 18 , wherein said plasmid comprises greater than about 80% supercoiled plasmid. 
     
     
         23 . The composition of  claim 18 , wherein said solution contains less than or equal to about 10 EU endotoxin per mg of plasmid. 
     
     
         24 . The composition of  claim 18 , wherein said solution contains less than or equal to about 1 EU endotoxin per mg of plasmid. 
     
     
         25 . The composition of  claim 18 , wherein said solution contains less than or equal to about 0.1 EU endotoxin per mg of plasmid. 
     
     
         26 . The composition of  claim 18 , wherein said solution contains less than or equal to about 1.0% RNA. 
     
     
         27 . The composition of  claim 18 , wherein said solution contains less than or equal to about 0.4% RNA. 
     
     
         28 . The composition of  claim 18 , wherein said solution contains less than or equal to about 1.0% protein. 
     
     
         29 . The composition of  claim 18 , wherein said solution contains less than or equal to about 0.20% protein. 
     
     
         30 . The composition of  claim 18 , wherein said solution contains less than or equal to about 1% genomic DNA. 
     
     
         31 . The composition of  claim 18 , wherein said solution contains less than or equal to about 0.01% genomic DNA.

Cited by (0)

No later patents cite this yet.

References (0)

No backward citations on record.